AP307A - Recombinant antibodies for human therapy. - Google Patents

Recombinant antibodies for human therapy. Download PDF

Info

Publication number: AP307A
Authority: AP; ARIPO
Prior art keywords: antibody; human; old world; world monkey; antigen
Prior art date: 1991-07-25

Application number

APAP/P/1992/000413A

Other languages

English (en)

Other versions

AP9200413A0 (en

Inventor

Roland A Newman

Nabil Hanna

Ronald W Raab

Original Assignee

Idec Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-25

Filing date

1992-07-27

Publication date

1994-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27112830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-07-27 Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp

1992-07-31 Publication of AP9200413A0 publication Critical patent/AP9200413A0/xx

1994-01-31 Application granted granted Critical

1994-01-31 Publication of AP307A publication Critical patent/AP307A/en

Links

YQRYSYDCERRVRK-UHFFFAOYSA-N CC1[N](C)(C2)C2C1 Chemical compound CC1[N](C)(C2)C2C1 YQRYSYDCERRVRK-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

APAP/P/1992/000413A 1991-07-25 1992-07-27 Recombinant antibodies for human therapy. AP307A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73506491A	1991-07-25	1991-07-25
US85628192A	1992-03-23	1992-03-23

Publications (2)

Publication Number	Publication Date
AP9200413A0 AP9200413A0 (en)	1992-07-31
AP307A true AP307A (en)	1994-01-31

Family

ID=27112830

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1992/000413A AP307A (en)	1991-07-25	1992-07-27	Recombinant antibodies for human therapy.

Country Status (24)

Country	Link
EP (3)	EP1715045A3 (es)
JP (1)	JP3048640B2 (es)
KR (1)	KR0137806B1 (es)
AP (1)	AP307A (es)
AT (2)	ATE237638T1 (es)
AU (1)	AU673499B2 (es)
BG (1)	BG62656B1 (es)
BR (1)	BR9206313A (es)
CA (1)	CA2114015C (es)
CZ (1)	CZ289472B6 (es)
DE (2)	DE69233011T2 (es)
DK (2)	DK0605442T3 (es)
ES (2)	ES2265005T3 (es)
FI (1)	FI117703B (es)
HU (2)	HUT70272A (es)
IL (1)	IL102640A0 (es)
MY (1)	MY121185A (es)
NO (1)	NO318097B1 (es)
NZ (1)	NZ243706A (es)
OA (1)	OA09879A (es)
PT (1)	PT100735B (es)
RO (1)	RO116404B1 (es)
SK (2)	SK285960B6 (es)
WO (1)	WO1993002108A1 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3443119B2 (ja)	1989-08-07	2003-09-02	ペプテックリミテッド	腫瘍壊死因子結合リガンド
US20030225254A1 (en)	1989-08-07	2003-12-04	Rathjen Deborah Ann	Tumour necrosis factor binding ligands
GB9022545D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Culture medium
US7192584B2 (en)	1991-03-18	2007-03-20	Centocor, Inc.	Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en)	1991-03-18	2001-09-04	New York University Medical Center	Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) *	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en)	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
ES2199216T3 (es) *	1991-07-15	2004-02-16	The Wellcome Foundation Limited	Produccion de anticuerpos.
US6136310A (en)	1991-07-25	2000-10-24	Idec Pharmaceuticals Corporation	Recombinant anti-CD4 antibodies for human therapy
EP1005870B1 (en)	1992-11-13	2009-01-21	Biogen Idec Inc.	Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en)	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
ATE183513T1 (de)	1993-06-03	1999-09-15	Therapeutic Antibodies Inc	Herstellung von antikörperfragmenten
US5429746A (en)	1994-02-22	1995-07-04	Smith Kline Beecham Corporation	Antibody purification
DK0759302T3 (da) *	1994-04-26	2000-11-13	Kanebo Ltd	Middel mod rheumatoid arthritis
US6627195B1 (en) *	1994-10-25	2003-09-30	Smithkline Beecham Corporation	Binding agents to CD23
WO1996017874A1 (en) *	1994-12-07	1996-06-13	F. Hoffmann-La Roche Ag	Monoclonal antibody fragments having immunosuppressant activity
US7153508B2 (en)	1995-06-07	2006-12-26	Biogen Idec Inc.	Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en)	1995-06-07	2007-02-13	Biogen Idec Inc.	Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en)	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
GB9624038D0 (en) *	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
US7033589B1 (en)	1997-02-20	2006-04-25	Biogen Idec Ma Inc.	γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6011138A (en) *	1997-02-20	2000-01-04	Idec Pharmaceuticals Corporation	Gamma-1 anti-human CD23 monoclonal antibodies
US6893636B2 (en) *	1997-02-20	2005-05-17	Biogen Idec Ma Inc.	Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
WO1999055369A1 (en) *	1998-04-28	1999-11-04	Smithkline Beecham Corporation	Monoclonal antibodies with reduced immunogenicity
GB9809839D0 (en)	1998-05-09	1998-07-08	Glaxo Group Ltd	Antibody
KR101023367B1 (ko)	1998-08-11	2011-03-18	바이오겐 아이덱 인크.	Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
KR20010103655A (ko)	1998-11-09	2001-11-23	케네쓰 제이. 울코트	키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법
HK1043312B (en)	1999-05-07	2006-07-28	Genentech, Inc.	Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
AU2001271614B2 (en) *	2000-07-03	2007-05-31	Catalent Pharma Solutions, Llc	Host cells containing multiple integrating vectors
EP2151493B1 (en) *	2000-07-03	2012-06-13	Catalent Pharma Solutions, LLC	Host cells containing multiple integrating vectors
AU2001270252B2 (en) *	2000-07-03	2007-02-08	Catalent Pharma Solutions, Llc	Expression vectors
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20050101012A1 (en)	2001-03-12	2005-05-12	Gerold Schuler	CD4+CD25+ regulatory T cells from human blood
EP1241249A1 (en) *	2001-03-12	2002-09-18	Gerold Schuler	CD4+CD25+regulatory T cells from human blood
TWI334439B (en)	2001-08-01	2010-12-11	Centocor Inc	Anti-tnf antibodies, compositions, methods and uses
US7384738B2 (en)	2002-03-28	2008-06-10	Bremel Robert D	Retrovirus-based genomic screening
US20040038304A1 (en)	2002-03-28	2004-02-26	Gala Design, Inc.	Antibody libraries
US8222033B2 (en)	2002-08-12	2012-07-17	Argos Therapeutics, Inc.	CD4+CD25− T cells and Tr1-like regulatory T cells
PL216630B1 (pl)	2002-10-17	2014-04-30	Genmab As	Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
US20070212301A1 (en) *	2003-11-07	2007-09-13	Amgen, Inc.	Monkey Immunoglobulin Sequences
WO2005048935A2 (en)	2003-11-14	2005-06-02	Brigham And Women's Hospital, Inc.	Methods of modulating immunity
US7858753B2 (en)	2004-03-30	2010-12-28	Glaxo Group Limited	Immunoglobulins
US7850962B2 (en)	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
TWI307630B (en)	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
CA2616859C (en) *	2005-08-03	2015-04-14	Fraunhofer Usa, Inc.	Compositions and methods for production of immunoglobulins
MX2008002161A (es) *	2005-08-15	2008-04-22	Arana Therapeutics Ltd	Anticuerpos quimericos con regiones de primate del nuevo mundo.
RU2008110060A (ru) *	2005-08-15	2009-09-27	Арана Терапьютикс Лимитед (Au)	Сконструированные антитела с каркасными участками приматов нового света
US7981414B2 (en) *	2005-12-20	2011-07-19	Cephalon Australia Pty Ltd	Anti-inflammatory dAb
EP1987064A4 (en)	2006-02-01	2010-04-07	Arana Therapeutics Ltd	DOMAIN ANTIBODY CONSTRUCT
PL2056858T3 (pl)	2006-08-11	2015-01-30	Csl Ltd	Leczenie stanów chorobowych płuc
TW200817438A (en)	2006-08-17	2008-04-16	Hoffmann La Roche	A conjugate of an antibody against CCR5 and an antifusogenic peptide
AU2007294575B2 (en)	2006-09-08	2013-06-27	Viela Bio, Inc.	Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008060814A2 (en)	2006-10-19	2008-05-22	Merck & Co., Inc.	ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF
AU2007319604B2 (en)	2006-10-19	2011-03-24	Csl Limited	High affinity antibody antagonists of interleukin-13 receptor alpha 1
CL2008000707A1 (es)	2007-03-13	2008-09-22	Hoffmann La Roche	Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
AR067584A1 (es)	2007-07-20	2009-10-14	Hoffmann La Roche	Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
JP5588983B2 (ja)	2008-08-11	2014-09-10	ウェルズファーゴバンクナショナルアソシエイション	マルチアームポリマーアルカノエートコンジュゲート
US8415291B2 (en)	2008-10-31	2013-04-09	Centocor Ortho Biotech Inc.	Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
GB2476681B (en)	2010-01-04	2012-04-04	Argen X Bv	Humanized camelid VH, VK and VL immunoglobulin domains
CN110251668A (zh)	2010-11-30	2019-09-20	霍夫曼-拉罗奇有限公司	低亲和力血脑屏障受体抗体及其用途
WO2012088422A1 (en)	2010-12-22	2012-06-28	Nektar Therapeutics	Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en)	2010-12-22	2021-01-19	Nektar Therapeutics	Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012166555A1 (en)	2011-05-27	2012-12-06	Nektar Therapeutics	Water - soluble polymer - linked binding moiety and drug compounds
US20140301675A1 (en) *	2011-10-31	2014-10-09	Jan-Niklas Keltsch	Packaging for single-handed manipulation
AU2016303688B2 (en)	2015-07-31	2023-06-15	Research Institute At Nationwide Children's Hospital	Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en)	2015-10-14	2017-04-20	Research Institute At Nationwide Children's Hospital	Hu specific interfering agents
US10465003B2 (en)	2016-02-05	2019-11-05	Janssen Biotech, Inc.	Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
AU2018206560B9 (en)	2017-01-04	2025-04-03	Research Institute At Nationwide Children's Hospital	Antibody fragments for the treatment of biofilm-related disorders
JP7514621B2 (ja)	2017-01-04	2024-07-11	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
EP3573658A4 (en)	2017-01-30	2021-07-21	Janssen Biotech, Inc.	ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
KR20190115042A (ko)	2017-02-07	2019-10-10	얀센 바이오테크 인코포레이티드	활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
US11746136B2 (en)	2017-03-15	2023-09-05	Research Institute At Nationwide Children's Hospital	Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CA3088856A1 (en)	2018-01-10	2019-07-18	Bioinvent International Ab	Novel combination and use of antibodies
EP3861021B1 (en)	2018-10-05	2025-02-12	Research Institute at Nationwide Children's Hospital	Compositions and methods for enzymatic disruption of bacterial biofilms
US11780911B2 (en)	2019-05-23	2023-10-10	Janssen Biotech, Inc.	Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CA3145385A1 (en)	2019-07-08	2021-01-14	Steven D. Goodman	Antibody compositions for disrupting biofilms
CN115768466A (zh)	2020-05-21	2023-03-07	詹森生物科技公司	用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
US20230322933A1 (en)	2020-06-04	2023-10-12	Bioinvent International Ab	Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
US20240092912A1 (en)	2021-03-09	2024-03-21	Bioinvent International Ab	Novel combinations of antibodies and uses thereof
WO2023161448A1 (en) *	2022-02-24	2023-08-31	Abnomx Bv	Human-like target-binding proteins
TW202336033A (zh)	2022-03-07	2023-09-16	瑞典商生物創新國際有限公司	抗體之新穎組合及用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2199216T3 (es) *	1991-07-15	2004-02-16	The Wellcome Foundation Limited	Produccion de anticuerpos.

1992
- 1992-07-24 BR BR9206313A patent/BR9206313A/pt not_active Application Discontinuation
- 1992-07-24 DK DK92917108T patent/DK0605442T3/da active
- 1992-07-24 DE DE69233011T patent/DE69233011T2/de not_active Expired - Fee Related
- 1992-07-24 NZ NZ243706A patent/NZ243706A/en unknown
- 1992-07-24 EP EP06010708A patent/EP1715045A3/en not_active Withdrawn
- 1992-07-24 EP EP92917108A patent/EP0605442B1/en not_active Expired - Lifetime
- 1992-07-24 SK SK5059-2005A patent/SK285960B6/sk not_active IP Right Cessation
- 1992-07-24 EP EP02012106A patent/EP1266965B1/en not_active Revoked
- 1992-07-24 IL IL102640A patent/IL102640A0/xx not_active IP Right Cessation
- 1992-07-24 ES ES02012106T patent/ES2265005T3/es not_active Expired - Lifetime
- 1992-07-24 JP JP5503072A patent/JP3048640B2/ja not_active Expired - Fee Related
- 1992-07-24 DE DE69233628T patent/DE69233628T2/de not_active Revoked
- 1992-07-24 HU HU9400201A patent/HUT70272A/hu unknown
- 1992-07-24 RO RO94-00095A patent/RO116404B1/ro unknown
- 1992-07-24 SK SK88-94A patent/SK285046B6/sk not_active IP Right Cessation
- 1992-07-24 WO PCT/US1992/006194 patent/WO1993002108A1/en not_active Ceased
- 1992-07-24 CA CA002114015A patent/CA2114015C/en not_active Expired - Fee Related
- 1992-07-24 KR KR1019940700217A patent/KR0137806B1/ko not_active Expired - Fee Related
- 1992-07-24 AT AT92917108T patent/ATE237638T1/de not_active IP Right Cessation
- 1992-07-24 DK DK02012106T patent/DK1266965T3/da active
- 1992-07-24 AU AU24255/92A patent/AU673499B2/en not_active Ceased
- 1992-07-24 CZ CZ1994149A patent/CZ289472B6/cs not_active IP Right Cessation
- 1992-07-24 AT AT02012106T patent/ATE327331T1/de active
- 1992-07-24 ES ES92917108T patent/ES2196002T3/es not_active Expired - Lifetime
- 1992-07-25 MY MYPI92001327A patent/MY121185A/en unknown
- 1992-07-27 AP APAP/P/1992/000413A patent/AP307A/en active
- 1992-07-27 PT PT100735A patent/PT100735B/pt not_active IP Right Cessation
1994
- 1994-01-21 NO NO19940219A patent/NO318097B1/no not_active IP Right Cessation
- 1994-01-24 OA OA60460A patent/OA09879A/en unknown
- 1994-01-24 FI FI940336A patent/FI117703B/fi active IP Right Grant
- 1994-01-24 BG BG98411A patent/BG62656B1/bg unknown
1995
- 1995-06-29 HU HU95P/P00595P patent/HU211881A9/hu unknown

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATURE, VOLUME 332; 24.03.88 REICHMANN et. al. pp 323-7 *
Proceedings of the Natioanl Academy of Science; Vol 88, No 11; 01.06.91 Wotanobe et.al. pp 4616-20 *

Also Published As

Publication number	Publication date
ES2265005T3 (es)	2007-02-01
EP1715045A3 (en)	2006-12-13
BG62656B1 (bg)	2000-04-28
AU2425592A (en)	1993-02-23
EP1266965B1 (en)	2006-05-24
HUT70272A (en)	1995-09-28
DK1266965T3 (da)	2006-09-25
FI940336A0 (fi)	1994-01-24
CA2114015C (en)	2002-12-10
HU9400201D0 (en)	1994-05-30
NZ243706A (en)	1994-08-26
WO1993002108A1 (en)	1993-02-04
BG98411A (bg)	1995-02-28
CZ14994A3 (en)	1994-07-13
EP1715045A2 (en)	2006-10-25
NO318097B1 (no)	2005-01-31
IL102640A0 (en)	1993-01-14
DE69233628T2 (de)	2007-04-26
DK0605442T3 (da)	2003-08-04
HU211881A9 (en)	1995-12-28
RO116404B1 (ro)	2001-01-30
NO940219L (no)	1994-03-25
AP9200413A0 (en)	1992-07-31
JP3048640B2 (ja)	2000-06-05
PT100735B (pt)	1999-07-30
DE69233628D1 (de)	2006-06-29
EP0605442B1 (en)	2003-04-16
AU673499B2 (en)	1996-11-14
KR0137806B1 (ko)	1998-04-30
OA09879A (en)	1994-09-15
JPH06509708A (ja)	1994-11-02
MY121185A (en)	2006-01-28
ATE237638T1 (de)	2003-05-15
FI117703B (fi)	2007-01-31
PT100735A (pt)	1993-10-29
BR9206313A (pt)	1995-04-11
SK285046B6 (sk)	2006-05-04
CA2114015A1 (en)	1993-02-04
SK285960B6 (sk)	2007-12-06
DE69233011T2 (de)	2003-11-06
SK8894A3 (en)	1994-09-07
DE69233011D1 (de)	2003-05-22
FI940336L (fi)	1994-03-10
EP0605442A4 (en)	1995-07-12
ATE327331T1 (de)	2006-06-15
EP1266965A2 (en)	2002-12-18
CZ289472B6 (cs)	2002-01-16
ES2196002T3 (es)	2003-12-16
EP0605442A1 (en)	1994-07-13
EP1266965A3 (en)	2003-01-02
NO940219D0 (no)	1994-01-21

Publication	Publication Date	Title
AP307A (en)	1994-01-31	Recombinant antibodies for human therapy.
US5658570A (en)	1997-08-19	Recombinant antibodies for human therapy
US5756096A (en)	1998-05-26	Recombinant antibodies for human therapy
AU717674B2 (en)	2000-03-30	Recombinant anti-CD4 antibodies for human therapy
IE84118B1 (en)		Recombinant antibodies for human therapy
RU2170256C2 (ru)	2001-07-10	Рекомбинантное антитело, специфичное к cd4, способ его получения и фармацевтическая композиция для лечения псориаза
HK1096708A (en)	2007-06-08	Recombinant antibodies for human therapy